Jul. 8 at 7:45 PM
$LCTX A speculative N play’... If OpRegen soon boosts Lineage commercial credibility, it might—paradoxically—become easier to monetize legacy assets.
A buyer might then think: “If Roche has confidence in Lineage, perhaps we should take another look at those other programs, like VAC2... maybe
$SANA :-) :-)
